PleoPharma, Inc. to Showcase Innovations at Centri Capital Conference in NYC

PleoPharma, Inc. to Present at the Centri Capital Conference

PleoPharma, Inc., a company dedicated to developing treatments for cannabis-related health issues, is set to present at the upcoming Centri Capital Conference in New York City on April 14, 2026. The presentation will take place at 8:30 a.m. Eastern Time, showcasing the company's innovative approach to tackling cannabis addiction and its related disorders.

Founded with a mission to address the increasing health concerns associated with cannabis use, PleoPharma is currently advancing its lead product, PP-01. This drug is heading into Phase 3 clinical trials and is positioned to be the first FDA-approved treatment for Cannabis Withdrawal Syndrome, a significant condition for individuals battling Cannabis Use Disorder (CUD). According to the U.S. government, approximately 20 million Americans were reported to have CUD in 2024, indicating an urgent need for effective therapeutic options.

The team behind PleoPharma boasts extensive experience in the field, having achieved multiple successful exits and over 50 product approvals worldwide. The company recently raised $36 million in Series B financing, bringing its total fundraising to over $60 million since its inception in 2019. This funding underlines a robust confidence among investors in PleoPharma’s potential to revolutionize cannabis addiction treatment.

At the Centri Capital Conference, PleoPharma's management is expected to delve into unique insights regarding cannabis health issues, discuss the implications of their study findings, and reveal their future plans to navigate the clinical landscape effectively.

Cannabis addiction remains a growing concern, with a rising trend of individuals seeking treatment. From 2018 to 2023, the number of people receiving care for cannabis-related health issues has grown by an average of 28% annually, underscoring the importance of PleoPharma's endeavors in this domain.

PleoPharma aims to not only provide solutions for addiction but also address the broader implications of cannabis use on mental health. PP-01 is designed to be a pivotal addition to the medical arsenal against cannabis dependency, a condition that can impact a significant portion of the population.

The upcoming conference is an excellent opportunity for PleoPharma to share their cutting-edge developments with investors and stakeholders while fostering relationships that could pave the way for further advancements in cannabis-related treatments. With a strategic focus, an expert team, and strong financial backing, PleoPharma is positioned to take a leading role in the shift towards comprehensive care for cannabis addiction.

For those interested in learning more about PleoPharma, additional information can be found on their official website, PleoPharma.com, or by contacting Jason Goodson, Chief Business Officer, via email at [email protected]. As PleoPharma moves forward, they continue to demonstrate a commitment to enhancing the quality of life for individuals affected by cannabis-related health challenges, making this presentation a key moment for the company and its stakeholders.

Forward-looking statements: This article includes forward-looking statements regarding PleoPharma's future operations and goals, which may not come to fruition due to various risks and uncertainties. Readers are warned against relying solely on these statements as indicators of future results.